Trial Search Results

Heparin and the Reduction of Thrombosis (HART) Trial

Heparin is frequently used in central venous catheters (CVCs) in post-operative cardiac patients. It remains unclear if a heparin infusion, compared to a normal saline infusion, prevents thrombosis of CVCs after surgery. This study will answer the question: does a low-dose heparin infusion (10 units/kg/h) prevent thrombosis, compared to a normal saline infusion, in patients less than one year of age after cardiac surgery?

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Heparin sulfate infusion at 10 units/kg/hour
  • Drug: Placebo infusion




Inclusion Criteria:

   - All infants < 1 year of age undergoing cardiac surgery at Lucile Packard Children's
   Hospital & #xA

Exclusion Criteria:

   - Known coagulopathy

   - History of clinically significant bleeding (GI, cranial, pulmonary)

   - Need for therapeutic heparinization

   - ECMO

Ages Eligible for Study

N/A - 1 Year

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
David Axelrod